ENDRA Life Sciences Inc.
Close on Oct 19, 2026
- Market cap
- $11.76M
- P/E (TTM)
- –
- Dividend yield
- –
About ENDRA Life Sciences
Electromedical & Electrotherapeutic Apparatus, SIC 3845
ENDRA Life Sciences Inc. is a medical technology company developing Thermo-Acoustic Enhanced Ultrasound (TAEUS), a non-invasive platform designed to evaluate tissue composition and assess liver fat at the point of care. The company focuses primarily on liver applications to detect and monitor metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Its initial liver product operates alongside conventional ultrasound systems to measure liver fat without requiring large capital equipment investments. The company targets pharmaceutical firms and clinical research organizations conducting metabolic trials, concierge primary care networks, bariatric and metabolic clinics, and broader primary and internal medicine practices.
The company is headquartered in Ann Arbor, Michigan, and conducts business in the United States and the European Union, where its MASLD application holds CE mark certification. In addition, ENDRA maintains a Digital Asset Treasury initiative investing in decentralized finance assets and uses third-party component suppliers and contract manufacturers to produce its TAEUS systems.
Summary of the business section of ENDRA Life Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ENDRA Life Sciences Inc.
- Founded
- 2007
- Headquarters
- Ann Arbor, MI
- Address
- 3600 Green Court, Suite 350 48105
- Phone
- (734) 335-0468
- Website
- endrainc.com
- Employees
- 11, Dec 31, 2025
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- RBSM LLP, Houston, Texas
Stock & identifiers
- Ticker
- NDRA
- Exchange
- Nasdaq
- IPO date
- Jun 30, 2017
- Shares outstanding
- 1M, Aug 14, 2026
- Public float
- $2.69M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-35 reverse, Nov 7, 2024; 1-for-50 reverse, Aug 20, 2024; 1-for-20 reverse, Dec 9, 2022
- SEC CIK
- 1681682
- CUSIP
- 29273B500
- ISIN
- US29273B5003
- LEI
- 6488380RAKK4NN716I68
- EIN
- 26-0579295
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Alexander Y. Tokman | Chief Executive Officer, Director | 101,926 |
| Richard Jacroux | Chief Financial Officer | 33,461 |
| Anthony Digiandomenico | Director | 136,589 |
| Lou Basenese | Director | 65,709 |
| Michael Harsh | Director | 65,710 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Alexander Tokman | $215.19K | $194.78K | $148.09K | $30 | – |
| FY2023 Alexander Tokman | $0 | $0 | $373.35K | $15320 | – |
| FY2022 Alexander Tokman | $0 | $0 | $430.87K | $29420 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 11 employees,”
Corporate history
Events identified from SEC filings